Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced presentations on Axumin (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, announced presentations on Axumin (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, Ill., from October 24 to 27, 2021. Details of selected oral and moderated poster presentations are listed below.

NOTE: Axumin (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by “*” discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted.

HIGHLIGHTED SCIENTIFIC PRESENTATIONS

Monday, October 25, 2021

 

Axumin (fluciclovine F 18) presentations

     

Category:

 

Genitourinary Cancer

Title:

 

Detectability Rates and Impact on Management From High-Sensitivity Total-Body 18F-Fluciclovine PET/CT Scans in Patients With Prostate Cancer Biochemical Recurrence

Presenter:

 

Soheila Fayeghi Azghadi, MD, Department of Radiation Oncology, Comprehensive Cancer Center, University of California Davis, Sacramento, Calif.

Session Title:

 

Poster Q&A 05 - Session 05 – Genitourinary Cancer, Hematology Malignancies, and Sarcoma and Cutaneous Tumors

Presentation Time:

 

1:30 PM CT

Location:

 

McCormick Place West, Outside Room W375

Presentation No.:

 

2532

 

 

 

Category:

 

Genitourinary Cancer

Title:

 

Randomized Trial of Conventional vs Conventional plus Fluciclovine (18F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses

Presenter:

 

Vishal Ramesh Dhere, MD, Winship Cancer Institute, Department of Radiation Oncology, Emory University, Atlanta, Ga.

Session Title:

 

Poster Q&A 05 - Session 05 – Genitourinary Cancer, Hematology Malignancies, and Sarcoma and Cutaneous Tumors

Presentation Time:

 

1:30 PM CT

Location:

 

McCormick Place West, Outside Room W375

Presentation No.:

 

2547

 

 

 

Investigational 18F-fluciclovine presentation

 

 

 

Category:

 

Central Nervous System

Session Title:

 

18F-Fluciclovine PET/CT to Distinguish Radiation Necrosis From Tumor Progression in Brain Metastases Treated With Stereotactic Radiosurgery: Results of a Prospective Pilot Study*

Presenter:

 

Martin C. Tom, MD, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio

Session Title:

 

51 Oral presentation

Presentation Time:

 

12:15 PM CT

Location:

 

McCormick Place West, Room W194 a/b

Presentation No.:

 

51

Blue Earth Diagnostics invites participants at the 2021 ASTRO Annual Meeting to attend the presentations above and visit the company at Exhibit Booth 665. Blue Earth Diagnostics is hosting an Industry-Expert Theater event, “The Role of PET in Post-Prostatectomy Radiotherapy,” with invited speaker Dr. Ashesh Jani, MD, MSEE, FASTRO, James C. Kennedy Professor, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga. The event will be held on Sunday, October 24, 2021, from 12:30 to 1:30 PM CT, in Theater 1, Exhibition Floor. For full session details and scientific presentation listings, please see the ASTRO online program here.


Related Content

News | Radiopharmaceuticals and Tracers

September 27, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 27, 2023
arrow
News | Radiation Therapy

September 27, 2023 — The American Society for Radiation Oncology (ASTRO) announced the three winning research proposals ...

Time September 27, 2023
arrow
News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
Feature | ASTRO | By Christine Book

September 26, 2023 — Ahead of the 65th American Society for Radiation Oncology Annual Meeting, ASTRO 2023, ITN’s ...

Time September 26, 2023
arrow
Feature | Magnetic Resonance Imaging (MRI) | By Robert L. Bard, MD, and Lennard M. Gettz, EdD

Since the advent of the magnetic resonance imaging (MRI) exam on human patients in the late 1970s, this innovation ...

Time September 25, 2023
arrow
News | X-Ray

September 21, 2023 — Scientists in Moscow have successfully engineered a prototype detector for X-ray and PET/CT ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
News | SNMMI

September 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), as a professional society ...

Time September 18, 2023
arrow
News | Radiation Oncology

September 13, 2023 — Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients ...

Time September 13, 2023
arrow
Subscribe Now